AMYLIN PHARMACEUTICALS INC 4

Accession 0001264124-12-000186

CIK 0000881464operating

View on SEC.gov Company Profile

Filed

Aug 9, 8:00 PM ET

Accepted

Aug 10, 6:35 PM ET

Size

32.9 KB

Accession

0001264124-12-000186

Insider Transaction Report

Form 4

Period: 2012-08-08

AMYLIN PHARMACEUTICALS INCAMLN

SULLIVAN JOSEPH P

Director

Transactions

Expiration (Short)
Non-Qualified Stock Option (right to buy)
2012-08-08−12,000→ 0 total
Exercise: $44.64Exp: 2017-05-23→ Common Stock (12,000 underlying)
Other
Phantom Stock-Deferred Compensation
2012-08-08$31.00/sh−17,451.3$540,990→ 8,961.7 total
→ Common Stock (17,451.3 underlying)
Other
Non-Qualified Stock Option (right to buy)
2012-08-08$31.00/sh−20,000$620,000→ 0 total
Exercise: $11.68Exp: 2016-05-27→ Common Stock (20,000 underlying)
Other
Non-Qualified Stock Option (right to buy)
2012-08-08$31.00/sh−20,000$620,000→ 0 total
Exercise: $13.18Exp: 2018-05-24→ Common Stock (20,000 underlying)
Other
Non-Qualified Stock Option (right to buy)
2012-08-08$31.00/sh−20,000$620,000→ 0 total
Exercise: $21.52Exp: 2017-04-29→ Common Stock (20,000 underlying)
Other
Non-Qualified Stock Option (right to buy)
2012-08-08$31.00/sh−12,000$372,000→ 0 total
Exercise: $22.89From: 2004-05-05Exp: 2014-05-05→ Common Stock (12,000 underlying)
Other
Non-Qualified Stock Option (right to buy)
2012-08-08$31.00/sh−20,000$620,000→ 0 total
Exercise: $27.30Exp: 2019-05-15→ Common Stock (20,000 underlying)
Other
Non-Qualified Stock Option (right to buy)
2012-08-08$31.00/sh−20,000$620,000→ 0 total
Exercise: $28.60From: 2003-09-12Exp: 2013-09-12→ Common Stock (20,000 underlying)
Expiration (Short)
Non-Qualified Stock Option (right to buy)
2012-08-08−12,000→ 0 total
Exercise: $41.34From: 2007-05-17Exp: 2016-05-17→ Common Stock (12,000 underlying)
Other
Phantom Stock-Deferred Compensation
2012-08-08$31.00/sh−260$8,060→ 0 total
Exercise: $0.00→ Common Stock (260 underlying)
Other
Common Stock
2012-08-08$31.00/sh−6,000$186,000→ 0 total
Other
Non-Qualified Stock Option (right to buy)
2012-08-08$31.00/sh−12,000$372,000→ 0 total
Exercise: $16.23From: 2005-05-25Exp: 2015-05-25→ Common Stock (12,000 underlying)
Expiration (Short)
Non-Qualified Stock Option (right to buy)
2012-08-08−12,000→ 0 total
Exercise: $31.77Exp: 2015-05-30→ Common Stock (12,000 underlying)
Other
Phantom Stock-Deferred Compensation
2012-08-08$31.00/sh−8,961.7$277,813→ 0 total
→ Common Stock (8,961.7 underlying)

Footnotes (4)

[F1]Represents a sale of shares to B&R Acquisition Company, a wholly-owned subsidiary of Bristol-Myers Squibb Company, either through directly tendering such shares or by virtue of a sale in the merger pursuant to the Agreement and Plan of Merger, dated as of June 29, 2012, among Bristol-Myers Squibb Company, B&R Acquisition Company and Amylin Pharmaceuticals, Inc. Includes 3,000 unvested restricted stock units that were cancelled at the effective time of the merger pursuant to the merger agreement in exchange for the right to receive cash payment for such restricted stock units at a price of $31.00 per restricted stock unit.
[F2]Pursuant to the Agreement and Plan of Merger, dated as of June 29, 2012, among Bristol-Myers Squibb Company, B&R Acquisition Company and Amylin Pharmaceuticals, Inc., these options, whether or not vested, were fully vested immediately prior to and cancelled at the effective time of the merger in exchange for the right to receive cash payment in the amount of $31.00 per option less the exercise price of such option.
[F3]Pursuant to the Agreement and Plan of Merger, dated as of June 29, 2012, among Bristol-Myers Squibb Company, B&R Acquisition Company and Amylin Pharmaceuticals, Inc., all options held by the reporting person with an exercise price above $31.00 per share were cancelled upon consummation of the merger.
[F4]Pursuant to the Agreement and Plan of Merger, dated as of June 29, 2012, among Bristol-Myers Squibb Company, B&R Acquisition Company and Amylin Pharmaceuticals, Inc., these phantom shares were cancelled in exchange for the right to receive cash payment for each phantom shares at a price of $31.00 per share. The distribution of cash to the reporting person will generally be in accordance with the distribution elections of the reporting person under the terms of Amylin's Deferred Compensation Plan.

Documents

1 file

4
edgardoc.xmlPrimary
PRIMARY DOCUMENT

Issuer

AMYLIN PHARMACEUTICALS INC

CIK 0000881464

→

Entity typeoperating

IncorporatedDE

Related Parties

filerCIK 0000881464

Filing Metadata

Form type: 4
Filed: Aug 9, 8:00 PM ET
Accepted: Aug 10, 6:35 PM ET
Size: 32.9 KB

View on SEC.gov